Merit Medical Systems, Inc. $MMSI Shares Bought by Assenagon Asset Management S.A.

Key Points

• Assenagon Asset Management boosted its stake in Merit Medical by 972.9% in Q4 to 211,891 shares (0.36% ownership) worth about $18.68 million.
• Merit beat quarterly expectations with $1.04 EPS (consensus $0.96) and $393.94M revenue (up 10.9% YoY), and issued FY2026 guidance of $4.010–$4.150 EPS.
• Analysts hold a consensus "Moderate Buy" (8 Buys, 3 Holds) with an average price target of $103.33 versus the recent share price near $69.31; the stock trades at a P/E of 32.69 and a 12‑month range of $66.34–$107.27.

Assenagon Asset Management S.A. lifted its holdings in shares of Merit Medical Systems, Inc. (NASDAQ:MMSI - Free Report) by 972.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 211,891 shares of the medical instruments supplier's stock after acquiring an additional 192,141 shares during the quarter. Assenagon Asset Management S.A. owned 0.36% of Merit Medical Systems worth $18,676,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. AQR Capital Management LLC grew its stake in Merit Medical Systems by 7.3% during the 1st quarter. AQR Capital Management LLC now owns 16,361 shares of the medical instruments supplier's stock valued at $1,730,000 after purchasing an additional 1,114 shares in the last quarter. Goldman Sachs Group Inc. raised its position in shares of Merit Medical Systems by 16.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 719,313 shares of the medical instruments supplier's stock valued at $76,039,000 after purchasing an additional 103,878 shares in the last quarter. Legal & General Group Plc raised its position in shares of Merit Medical Systems by 2.0% in the 2nd quarter. Legal & General Group Plc now owns 188,787 shares of the medical instruments supplier's stock valued at $17,648,000 after purchasing an additional 3,705 shares in the last quarter. Rhumbline Advisers boosted its stake in shares of Merit Medical Systems by 7.1% during the 2nd quarter. Rhumbline Advisers now owns 167,643 shares of the medical instruments supplier's stock valued at $15,671,000 after buying an additional 11,089 shares during the last quarter. Finally, Prudential Financial Inc. grew its position in shares of Merit Medical Systems by 7.5% during the second quarter. Prudential Financial Inc. now owns 61,266 shares of the medical instruments supplier's stock worth $6,210,000 after buying an additional 4,300 shares in the last quarter. Institutional investors and hedge funds own 99.66% of the company's stock.

Merit Medical Systems Stock Performance

MMSI stock opened at $69.31 on Friday. The stock's 50 day simple moving average is $77.12 and its 200 day simple moving average is $82.44. Merit Medical Systems, Inc. has a 12-month low of $66.34 and a 12-month high of $107.27. The firm has a market cap of $4.12 billion, a P/E ratio of 32.69, a P/E/G ratio of 1.96 and a beta of 0.62. The company has a current ratio of 4.34, a quick ratio of 2.95 and a debt-to-equity ratio of 0.46.

Merit Medical Systems (NASDAQ:MMSI - Get Free Report) last released its quarterly earnings data on Tuesday, February 24th. The medical instruments supplier reported $1.04 EPS for the quarter, topping analysts' consensus estimates of $0.96 by $0.08. Merit Medical Systems had a net margin of 8.48% and a return on equity of 13.82%. The firm had revenue of $393.94 million during the quarter, compared to the consensus estimate of $390.77 million. During the same quarter in the previous year, the company posted $0.93 earnings per share. The firm's revenue was up 10.9% on a year-over-year basis. Merit Medical Systems has set its FY 2026 guidance at 4.010-4.150 EPS. As a group, equities research analysts predict that Merit Medical Systems, Inc. will post 3.37 EPS for the current year.

Wall Street Analyst Weigh In

MMSI has been the subject of a number of research analyst reports. Piper Sandler dropped their price target on shares of Merit Medical Systems from $113.00 to $106.00 and set an "overweight" rating for the company in a research note on Wednesday, February 18th. Robert W. Baird set a $108.00 price objective on shares of Merit Medical Systems in a research note on Tuesday, December 16th. Barrington Research raised their price objective on shares of Merit Medical Systems from $106.00 to $109.00 and gave the stock an "outperform" rating in a report on Wednesday, February 25th. Needham & Company LLC dropped their target price on shares of Merit Medical Systems from $108.00 to $101.00 and set a "buy" rating for the company in a research report on Wednesday, February 25th. Finally, Canaccord Genuity Group upped their target price on shares of Merit Medical Systems from $93.00 to $99.00 and gave the company a "buy" rating in a research note on Wednesday, December 17th. Eight investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $103.33.

Merit Medical Systems Profile

Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company's product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.

Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.